BMS signs licensing deal worth up to $8.4bn for SystImmune’s BL-B01D1
BL-B01D1 is a bispecific topoisomerase inhibitor-based ADC, which is presently in a Phase 1 study in patients with…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Dec 23
BL-B01D1 is a bispecific topoisomerase inhibitor-based ADC, which is presently in a Phase 1 study in patients with…
12 Dec 23
The financing will be used to optimize breakthrough applications of the company’s Z-Screen platform and advance an internal…
11 Dec 23
BioNTech will build and operate a clinical-scale mRNA manufacturing facility leveraging its digitally enabled modular manufacturing units, the…
11 Dec 23
According to the results, 200mg twice daily iptacopan showed superiority against placebo in delivering clinically meaningful and statistically…
11 Dec 23
The collaboration brings together professional advantages of Nona Biosciences and Evive Biotech, aiming to accelerate the process of…
08 Dec 23
The funding will be used to solidify the firm’s AlphaDirect technology, which is a Pb212 isolation method, and…
08 Dec 23
Ponvory is a daily oral selective sphingosine-1-phosphate receptor 1 modulator, approved by the US FDA and Health Canada…
08 Dec 23
First global Phase 3 study to report positive results with an anti-CD38 therapy in combination with VRd in…
08 Dec 23
The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools…
07 Dec 23
The proposed acquisition will include Cerevel’s clinical-stage pipeline of assets focused on psychiatric and neurological disorders, which will…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates